GlassScriptPhysician profile
Beatrice Buhuro
NPI 1629499561
$1,962.75
in general payments reported to CMS, 2019-2025
27 companies · $22.13 in 2025
The $22.13 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $337 · 2023: $1,115 · 2024: $488 · 2025: $22.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,625.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $409.71 | 2023-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $382.41 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Sumitomo Pharma America, INC. | $155.84 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $149.99 | 2022 | |
| Glaxosmithkline, LLC. | $131.49 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $88.94 | 2022-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.89 | 2023-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $55.97 | 2022 | |
| Daiichi Sankyo INC. | $46.16 | 2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $40.87 | 2023-2024 | Airsupra |
| Harmony Biosciences LLC | $38.75 | 2023 | Wakix |
| Novocure INC. | $33.74 | 2024 | Optune |
| Novartis Pharmaceuticals Corporation | $33.03 | 2023 | |
| Exact Sciences Corporation | $31.94 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $31.86 | 2024 | Jardiance, Mounjaro |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $29.44 | 2024 | Rexulti |
| Pfizer INC. | $28.20 | 2023 | |
| Corium, LLC | $26.84 | 2023 | Adlarity |
| Amgen INC. | $26.68 | 2023 | Otezla, Repatha |
| Hologic Sales and Service, LLC | $25.27 | 2022 | |
| Pharmaessentia USA Corporation | $22.13 | 2025 | Besremi |
| Insulet Corporation | $18.99 | 2023 | Omnipod |
| Boston Scientific Corporation | $18.78 | 2024 | Wavewriter Alpha Prime 16 |
| Nevro Corp. | $17.45 | 2024 | Senza |
| Merck Sharp & Dohme LLC | $17.43 | 2023 | Belsomra |
| Medtronic, INC. | $15.42 | 2022 | |
| Dexcom, INC. | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beatrice Buhuro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.